EYPT - EyePoint Pharma announces 12-month phase 1 data for its treatment for eye disorder wAMD

• EyePoint Pharmaceuticals ( NASDAQ: EYPT ) on Friday announced what it deemed to be positive 12-month data from its phase 1 trial for its EYP-1901 therapy as a potential every six-month treatment for wet age-related macular degeneration (wAMD), a chronic eye disorder.
• EYPT said stable visual acuity and optical coherence tomography was observed in patients in the early-stage trial, called DAVIO, from a single treatment with EYP-1901.
• There were no dose limiting toxicities and serious adverse events observed in the trial.
• The data is being presented at the 2022 annual meeting of the American Society of Retina Specialists.
• EYPT said it expects to begin dosing patients in the phase 2 trial, called DAVIO2, for EYP-1901 in wAMD in Q3 2022, with topline data anticipated in H2 2023.
• EYPT stock +0.8% to $8.21 in morning trading.

For further details see: